Compare LWAY & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | OCGN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 492.5M |
| IPO Year | 1995 | 2014 |
| Metric | LWAY | OCGN |
|---|---|---|
| Price | $24.18 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $34.50 | $9.75 |
| AVG Volume (30 Days) | 84.6K | ★ 7.5M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.33 | 31.58 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $17.28 | $1,718.38 |
| P/E Ratio | $86.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.31 | $0.73 |
| 52 Week High | $34.20 | $2.73 |
| Indicator | LWAY | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 34.84 |
| Support Level | $23.01 | $1.35 |
| Resistance Level | $25.37 | $1.92 |
| Average True Range (ATR) | 1.15 | 0.09 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 20.15 | 1.92 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").